01
Sep,2023
News
AcadeMab Biomedical and Academia Sinica enter into exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids
Academia Sinica and AcadeMab Biomedical have reached an exclusive licensing agreement. The project includes dengue fever mRNA vaccine and a series of novel cationic lipids. Under the terms of the agreement, AcadeMab will establish a new "mRNA Vaccine R&D Department" for the development, manufacturing of dengue mRNA vaccine and implementing pre-clinical and clinical trials as well as commercializing cationic lipids.
As the global dengue fever epidemic continues to rise, AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term. In addition, AcadeMab will leverage its cationic lipid platform to lower the barriers to developing mRNA delivery technology and help create an ecosystem for mRNA vaccine manufacturing.
As the global dengue fever epidemic continues to rise, AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term. In addition, AcadeMab will leverage its cationic lipid platform to lower the barriers to developing mRNA delivery technology and help create an ecosystem for mRNA vaccine manufacturing.
AcadeMab has initiated a phase I clinical trial at multiple clinical centers, including National Taiwan University Hospital, National Taiwan University Cancer Center, and National Cheng Kung University Hospital.
The first subject of this trail has enrolled, and a total of 30 subjects are expected to participate in this clinical trial.
研⽣精準醫療抗體新藥AM-928 取得美國IND 對多種癌症治療具臨床潛⼒
研⽣今（6）⽇宣布，抗體新藥AM-928已經取得美國⻝品藥物管理局（FDA）的新藥臨床試驗（IND）許可，將針對晚期實體癌症病患進⾏第⼀期臨床試驗。研⽣成⽴於2020年中，在2023年初即有新藥取得美國FDA IND，展現台灣⽣技公司的世界級研發⽔準。
